LICENSE AGREEMENTLicense Agreement • November 19th, 2021 • New York
MERCK SHARP & DOHME CORP., a New Jersey corporation having its primary address at 2000 Galloping Hill Road, Kenilworth, New Jersey, 07033, United States, and its registered office at 820 Bear Tavern Road, West Trenton, New Jersey, 08628, United States (“MSD”);
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 27th, 2022 • Rhode Island
This Exclusive License Agreement (this “Agreement”) is entered into as of January 25, 2021 , 2021 (the “Effective Date”), by and between Elkurt Inc. a Rhode Island corporation, with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc, a Delaware corporation with an address at 19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”).
Contract Number]Advance Purchase Agreement • January 11th, 2021
ADVANCE PURCHASE AGREEMENT (“APA”)1 for the development, production, advance purchase and supply of a COVID-19 vaccine for EU Member States
MODEL CONSORTIUM AGREEMENT DAgreement • May 18th, 2020
Scenario - Each party owns the IPR in the results which it creates and grants each of the other parties a non-exclusive licence to use those results for the purposes of the Project.
REAL-WORLD EPIDEMIOLOGICAL EVIDENCE COLLABORATION AGREEMENTReal-World Epidemiological Evidence Collaboration Agreement • January 12th, 2021
dated as of January 6, 2021 (this “Agreement”) by and between the Israeli Ministry of Health, acting on its own behalf and on behalf of the State of Israel (the “MoH”), and Pfizer Inc., a Delaware corporation (together with its Affiliates, “PFIZER”) (each, a “Party” and, collectively, the “Parties”).
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVEPatent License Agreement – Exclusive • March 22nd, 2024
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks), Appendix E (Commercialization Plan). Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
EX-10.4 10 a2236470zex-10_4.htm EX-10.4June 7th, 2022
This Collaboration Agreement relating to the development, manufacture and commercialisation of zoliflodacin is entered into on the 4th day of July 2017 (the “Effective Date”) by and between:
Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. COVID COLLABORATION AND LICENSE AGREEMENTCovid Collaboration and License Agreement • September 8th, 2021
NOW THEREFORE, in consideration of the foregoing premises and the following mutual covenants and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
LICENSE AGREEMENTLicense Agreement • November 8th, 2015 • England
This LICENSE AGREEMENT (the “Agreement”) is made as of September 15, 2014 (the “Effective Date”) by and between Gilead Sciences Limited an Irish corporation having its principal place of business at IDA Business & Technology Park, Carigtohill, Co. Cork, Ireland
Patent Sublicense AgreementPatent Sublicense Agreement • March 16th, 2022 • Pennsylvania
This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and BioNTech AG, a German corporation having its principal place of business at An der Goldgrube 12, 55131 Mainz, Germany (“Company”). This Agreement is effective as of July 14, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.
GLOBAL LONG TERM AGREEMENTGlobal Long Term Agreement • October 8th, 2021 • New York
This Global Long Term Agreement is made as of September 4, 2020, and effective as of May 1, 2020 (the “Effective Date”) among Lonza Ss Ltd., having an address at Münchensteinerstrasse 38, 4002 Basel, Switzerland] (“LONZA SALES”), Lonza Ltd., having an address at Münchensteinerstrasse 38, 4002 Basel, Switzerland (“LONZA LTD”, and together with LONZA SALES, “LONZA”), and ModernaTX, Inc., with an address at 200 Technology Square, Cambridge, MA 02139 USA (“MODERNA” or “CLIENT”) (each, a “Party” and, collectively, the “Parties”).
SUPPLY AND LICENSE AGREEMENT BETWEENSupply and License Agreement • July 20th, 2021
This Supply and License Agreement (the “Agreement”) is entered into and made effective as of July 30, 2020 (the “Effective Date”), by and between Serum Institute of India Private Limited., an Indian company having its principal place of business at 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates). Novavax and SIIPL may each be referred to herein individually as a “Party” and collectively as the “Parties.”
COVID-19 Outbreak Response Agreement (ver 3.1) Agreement SummaryAgreement • August 25th, 2022 • England and Wales
THIS AGREEMENT (the “Agreement”) is between Awardee and the Coalition for Epidemic Preparedness Innovations (“CEPI”) and is effective as of the date of the last signature, below (the “Effective Date”). Each party to this Agreement may be referred to individually as a “Party” and together as the “Parties.” This Agreement sets out the terms and conditions governing the performance and funding of the Project (as defined herein). It also reflects the Parties’ mutual commitment to develop a safe and effective vaccine against SARS-CoV-2, to test and obtain regulatory approval for the vaccine as rapidly as possible, consistent with patient safety and achieving vaccine quality, and to ensure the manufacture and distribution of sufficient quantities of the vaccine to meet global demand at affordable prices in the country of use. As a condition of this funding award, the Parties enter into this Agreement by having their authorised representatives sign below.
LICENSE AGREEMENTLicense Agreement • September 9th, 2017 • England and Wales
This LICENSE AGREEMENT (the “Agreement”) is made as of (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at Chemin Louis-Dunant 17, Geneva 1202, Switzerland (“Licensor”), and a company registered under the laws of , and having a registered office at
ContractInter-Institutional Agreement • May 18th, 2020
This model document is the work product of a coalition of technology transfer professionals, university general counsel and outside counsel. This document is intended to serve as a starting point, and should be tailored to meet your specific requirements. This document should not be construed as legal advice for any particular facts or circumstances.
MODEL LICENSE AGREEMENT FOR USE BY NON-PROFITS:Model License Agreement • May 18th, 2020
LICENSEE QUALIFICATIONS: Not-for-profit institutions such as Product Development Partnerships (PDP) and Non-Government Organizations (NGOs) with a demonstrated commitment to diligence in providing broad global access to technologies, products and services consistent with an acceptable Development Plans.
COREModel Grant Agreement • September 18th, 2020
The IMI Joint Undertaking (the "IMI JU"), represented for the purposes of this agreement by [forename, name], its Executive Director or her/his duly authorised representative,
COREGrant Agreement • June 17th, 2021
The IMI Joint Undertaking (the "IMI JU"), represented for the purposes of this agreement by [forename, name], its Executive Director or her/his duly authorised representative,
EX-10.21 27 d427310dex1021.htm EX-10.21Letter Agreement • April 25th, 2022 • Delaware
This letter agreement (including all appendices and attachments hereto, the “Letter Agreement”) is entered into in connection with the investment by the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax-exempt private foundation, of eight million dollars ($8,000,000.00) (the “Foundation Investment”) in Series D Preferred Stock of Arsanis, Inc. (the “Company”) at a purchase price of $3.2457 per share in accordance with the terms of a Series D Preferred Stock Purchase Agreement dated April 24, 2017 (the “Purchase Agreement”). The Foundation is making the Foundation Investment to induce the Company to perform the Global Access Commitments set forth herein, and the Company acknowledges and agrees that it would not undertake such Global Access Commitments absent the Foundation Investment. The Foundation Investment will be made in accordance with the provisions of the Purchase Agreement and this Letter Agreement (collectively, and together with a
CAVD DATA & MATERIALS SHARING AGREEMENTSharing Agreement • October 20th, 2020
WHEREAS, each Party is a member of a Funded Center or Consortium in the Collaboration for AIDS Vaccine Discovery (CAVD) - a network of centers and consortia funded by the Bill & Melinda Gates Foundation (the Foundation), to support the implementation of the scientific strategic plan of the Global HIV Vaccine Enterprise (the Enterprise).
EX-10 9 filename9.htmLetter Agreement • July 21st, 2023
This amended and restated letter agreement (including all appendices and attachments hereto, the “Letter Agreement”) is entered into on November 7, 2013 and effective as of September 12, 2012, in connection with the investment by the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax-exempt private foundation, of a total of six million and eight hundred thousand dollars ($6,800,000) for Series A Preferred Stock of Visterra, Inc. (the “Company”) at the per share price of $1.00 (the “Foundation Investment”). This Letter Agreement replaces the letter agreement, dated September 12, 2012, between the Company and the Foundation in its entirety. The Foundation is making the Foundation Investment in accordance with the provisions of the investment documents executed in connection with the closing of the supplemental Series A Preferred Stock offering (“Supplemental Closing”), including, without limitation, the Amended and Restated Series A Convertibl
EX-10.7 6 dvax-ex107_312.htm EX-10.7England and Wales • January 25th, 2022
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
EZ Start License Agreement University Case Title:________________________ University Case Number(s):License Agreement • March 10th, 2016 • Massachusetts
This document is for discussion purposes only and does not constitute a binding agreement or letter of intent between the parties. The terms of any transaction between the parties will be subject to the negotiation and execution of a definitive agreement satisfactory to the parties. Unless and until a definitive agreement is executed by the parties, neither party is under any legal obligation of any kind with respect to any transaction relating to the subject matter stated herein. Until such a definitive agreement is executed, either party may determine not to proceed with the proposed transaction at any time and for any reason [To be removed in Final document sent for signatures].
EX-10.2 3 ex10-2.htmOntario • September 7th, 2022
PLEASE NOTE: CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
PROJECT COLLABORATION AGREEMENTProject Collaboration Agreement • May 18th, 2020
CONFIDENTIAL DISCLOSURE AGREEMENTConfidential Disclosure Agreement • May 18th, 2020
WHEREAS, representatives of …………… and WHO intend to hold discussions, during which may disclose to WHO certain information and data relating
GLOBAL ACCESS COMMITMENTS AGREEMENTAccess Commitments Agreement • August 29th, 2022 • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, this “GACA”), is entered into as of date of last signature below (“Effective Date”) by and between the Bill and Melinda Gates Foundation, a Washington Charitable Trust (the “Foundation”) and Novavax, Inc., a Delaware corporation based in Maryland (“Novavax” or the “Company”) in connection with the Foundation making a charitable grant of up to eighty nine million, eighty three thousand three hundred twelve U.S. dollars ($89,083,312.00) to Company (the “Grant”) and is subject to the terms and conditions of the Grant Agreement and related documents, including but not limited to this GACA. Each of the parties named above may be referred to herein as a “Party” and collectively as the “Parties”. Capitalized terms not defined herein shall have the same meaning as in the Grant Agreement. In consideration of the Foundation making the grant on the terms and conditions in the Grant Agreement and h
TEMPLATE COLLABORATION AGREEMENT WITH WHOTemplate Collaboration Agreement With Who • May 18th, 2020
- the World Health Organization, having its headquarters at 20, avenue Appia, 1211 Geneva 27, Switzerland (hereinafter referred to as "WHO").
AgreementEngland • October 28th, 2021
This Agreement (“Agreement”) is entered into as of the date of last signature by and between Coalition for Epidemic Preparedness Innovations, having an address of PO Box 123, Torshov, N-0412 Oslo, Norway (“CEPI”), and Dynavax Technologies Corporation, having an address of 2100 Powell Street, Suite 900, Emeryville, CA 94608, USA (“Dynavax”). Each of CEPI and Dynavax is referred to herein individually as a “Party” and are collectively referred to herein as the “Parties.”
LICENSE AGREEMENTLicense Agreement • October 23rd, 2019 • New York
This License Agreement (“Agreement”) is made as of the 23rd of October 2019 (“Effective Date”) by and between Pfizer Inc., a biopharmaceutical corporation having offices at 235 E 42nd Street, New York, New York 10017-5703 (“Pfizer”), and the Medicines Patent Pool Foundation, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at 7 Rue de Varembé, Geneva 1202, Switzerland (“MPP”). Each of Pfizer and MPP is referred to in this Agreement as a “ Party.” Pfizer and MPP are collectively referred to in this Agreement as the “Parties.”
AMENDED AND RESTATED LICENSE AGREEMENTAmended And • November 2nd, 2020 • England
This AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”) is made as of BBBBBBBBBBBB (the “Effective Date”) by and among Gilead Sciences, Inc. a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, California 94404, USA (“Gilead”), the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at 150 route de Ferney, P.O. Box 2100, CH-1211 Geneva 2, Switzerland
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • May 18th, 2020 • New York
This Research Collaboration Agreement, with an Effective Date of ... 2015 is made by and between the University 1, (“ ”), University 2, located at ( “ ”), Center, located at, , (“”), University 3 acting for and on behalf of its School of Medicine, with offices at ( “ ”), , located at
ContractManagement Agreement • May 18th, 2020
This model document is the work product of a coalition of technology transfer professionals, university general counsel and outside counsel. This document is intended to serve as a starting point, and should be tailored to meet your specific requirements. This document should not be construed as legal advice for any particular facts or circumstances.
Funding AgreementEngland and Wales • August 23rd, 2021
THIS AGREEMENT is between Valneva SE (“Awardee” or “You”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) and is effective as of the Effective Date. Each party to this Agreement may be referred to individually as a “Party” and together as the “Parties.” This Agreement sets out the
EX-10.9 4 fs42021a1ex10-9_petraacq.htm GLOBAL HEALTH AGREEMENT BY AND BETWEEN REVELATION AND AXA IM PRIME IMPACT FUND DATEDLetter Agreement • August 10th, 2022 • Delaware
This global health letter agreement (“Global Health Agreement”) is entered into by and between Revelation Biosciences, Inc. a Delaware corporation (the “Company”) and AXA Prime Impact Master Fund I SCA SICAV-RAIF (the “Investor” or “AXA IM Impact Fund”) in connection with its commitment to purchase certain shares of the Company’s Series A Preferred Stock (the “Shares”) in accordance with the terms of that certain Series A Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase Agreement”), at a price of $6.36 per share (for a total of $3,999,994.80) (the “Investment”).
